Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer
Artiva Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
Artiva Biotherapeutics reported early data on its off-the-shelf NK cell therapy in combination with rituximab, suggesting the combo could shrink tumors in non-Hodgkin lymphoma patients who have already tried many other cancer therapies.
SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101. AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell product candidate being investigated in combination with rituximab for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). The presentation will take place on Monday, June 5, during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell being investigated in combination with rituximab for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
HEIDELBERG, Germany and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”), and Artiva Biotherapeutics Inc. (“Artiva”), both immuno-oncology companies focused on developing and commercializing therapies utilizing the innate immune system, today announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed’s Innate Cell Engager (ICE®) AFM13 and Artiva’s cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101.
SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, announced today the presentation of preclinical efficacy data combining anti-CD38 antibodies with AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, in multiple myeloma models. The data will be presented at the 64th American Society of Hematology (ASH 2022) Annual Meeting & Exposition taking place December 10-13, in New Orleans.